Last reviewed · How we verify
CS060380
CS060380 is a small molecule that targets the SGLT2 receptor.
CS060380 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CS060380 |
|---|---|
| Also known as | Placebo |
| Sponsor | Cascade Pharmaceuticals, Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, CS060380 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (PHASE2)
- A Study of CS060380 Tablets in Patients With MASH and Obesity (PHASE2)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CS060380 CI brief — competitive landscape report
- CS060380 updates RSS · CI watch RSS
- Cascade Pharmaceuticals, Inc portfolio CI